Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nicotinic Mechanisms in the Treatment of Psychotic Disorders: A Focus on the α7 Nicotinic Receptor
Ann Olincy, Robert Freedman
Handbook of experimental pharmacology (2012), pp. 211-232
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Sensory Processing Dysfunction in the Personal Experience and Neuronal Machinery of Schizophrenia
Daniel C. Javitt, Robert Freedman
American Journal of Psychiatry (2014) Vol. 172, Iss. 1, pp. 17-31
Open Access | Times Cited: 355
nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives
Vinay Parikh, Munir Gunes Kutlu, Thomas J. Gould
Schizophrenia Research (2016) Vol. 171, Iss. 1-3, pp. 1-15
Open Access | Times Cited: 86
Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia
Gerhard Groß, Karsten Wicke, Karla Drescher
Naunyn-Schmiedeberg s Archives of Pharmacology (2012) Vol. 386, Iss. 2, pp. 155-166
Closed Access | Times Cited: 79
Human Brain Imaging of α7 nAChR with [18F]ASEM: a New PET Radiotracer for Neuropsychiatry and Determination of Drug Occupancy
Dean F. Wong, Hiroto Kuwabara, Martin G. Pomper, et al.
Molecular Imaging and Biology (2014) Vol. 16, Iss. 5, pp. 730-738
Open Access | Times Cited: 71
Heterogeneity in Dopamine Neuron Synaptic Actions Across the Striatum and Its Relevance for Schizophrenia
Nao Chuhma, Susana Mingote, Abigail Kalmbach, et al.
Biological Psychiatry (2016) Vol. 81, Iss. 1, pp. 43-51
Open Access | Times Cited: 69
The challenge of reducing smoking in people with serious mental illness
Ratika Sharma, Coral Gartner, Wayne Hall
The Lancet Respiratory Medicine (2016) Vol. 4, Iss. 10, pp. 835-844
Open Access | Times Cited: 65
Neurocognitive endophenotypes in schizophrenia: Modulation by nicotinic receptor systems
Kristen M. Mackowick, Mera S. Barr, Victoria C. Wing, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2013) Vol. 52, pp. 79-85
Open Access | Times Cited: 62
Positive allosteric modulation of M 1 and M 4 muscarinic receptors as potential therapeutic treatments for schizophrenia
Samantha E. Yohn, P. Jeffrey Conn
Neuropharmacology (2017) Vol. 136, pp. 438-448
Open Access | Times Cited: 57
Cortical synaptic NMDA receptor deficits in α7 nicotinic acetylcholine receptor gene deletion models: Implications for neuropsychiatric diseases
Hong Lin, Fu‐Chun Hsu, Bailey Baumann, et al.
Neurobiology of Disease (2013) Vol. 63, pp. 129-140
Open Access | Times Cited: 56
Cortical parvalbumin GABAergic deficits with α7 nicotinic acetylcholine receptor deletion: implications for schizophrenia
Hong Lin, Fu‐Chun Hsu, Bailey Baumann, et al.
Molecular and Cellular Neuroscience (2014) Vol. 61, pp. 163-175
Open Access | Times Cited: 55
Cortical parvalbumin and somatostatin GABA neurons express distinct endogenous modulators of nicotinic acetylcholine receptors
Michael P. Demars, Hirofumi Morishita
Molecular Brain (2014) Vol. 7, Iss. 1
Open Access | Times Cited: 53
The role of nicotinic cholinergic neurotransmission in delusional thinking
Michael Caton, Enrique L. M. Ochoa, Francisco J. Barrantes
Schizophrenia (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 41
Novel Antischizophrenia Treatments
Mark A. Geyer, Gerhard Groß
Handbook of experimental pharmacology (2012)
Open Access | Times Cited: 51
Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
Kenji Hashimoto
Current Pharmaceutical Design (2015) Vol. 21, Iss. 26, pp. 3797-3806
Open Access | Times Cited: 49
Drug Tolerance: A Known Unknown in Translational Neuroscience
Anton Bespalov, Reinhold Müller, Ana-Lucia Relo, et al.
Trends in Pharmacological Sciences (2016) Vol. 37, Iss. 5, pp. 364-378
Closed Access | Times Cited: 42
Neural oscillatory deficits in schizophrenia predict behavioral and neurocognitive impairments
Antı́gona Martı́nez, Pablo A. Gaspar, Steven A. Hillyard, et al.
Frontiers in Human Neuroscience (2015) Vol. 9
Open Access | Times Cited: 41
Reduced Short-Latency Afferent Inhibition in Prefrontal but not Motor Cortex and Its Association With Executive Function in Schizophrenia: A Combined TMS-EEG Study
Yoshihiro Noda, Mera S. Barr, Reza Zomorrodi, et al.
Schizophrenia Bulletin (2017) Vol. 44, Iss. 1, pp. 193-202
Open Access | Times Cited: 41
Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers
Verner Knott, Sara de la Salle, Joëlle Choueiry, et al.
Pharmacology Biochemistry and Behavior (2015) Vol. 131, pp. 119-129
Closed Access | Times Cited: 38
Dementia praecox redux: A systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia
Arann Rowe, Louise Mercer, Valentina Casetti, et al.
Journal of Psychopharmacology (2015) Vol. 29, Iss. 2, pp. 197-211
Closed Access | Times Cited: 37
High-affinity nicotinic acetylcholine receptor expression and trafficking abnormalities in psychiatric illness
Alan S. Lewis, Marina R. Picciotto
Psychopharmacology (2013) Vol. 229, Iss. 3, pp. 477-485
Open Access | Times Cited: 37
Schizophrenia and visual backward masking: a general deficit of target enhancement
Michael H. Herzog, Maya Roinishvili, Eka Chkonia, et al.
Frontiers in Psychology (2013) Vol. 4
Open Access | Times Cited: 37
Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study
Morozova Ma, T. A. Lepilkina, G. Rupchev, et al.
CNS Spectrums (2013) Vol. 19, Iss. 4, pp. 316-323
Closed Access | Times Cited: 37
The role of macrophage polarization on bipolar disorder: Identifying new therapeutic targets
Bruna Maria Ascoli, Luíza Paul Géa, Rafael Colombo, et al.
Australian & New Zealand Journal of Psychiatry (2016) Vol. 50, Iss. 7, pp. 618-630
Open Access | Times Cited: 33
Drug repurposing and emerging adjunctive treatments for schizophrenia
Jan Malte Bumb, Frank Enning, F. Markus Leweke
Expert Opinion on Pharmacotherapy (2015) Vol. 16, Iss. 7, pp. 1049-1067
Closed Access | Times Cited: 32
Preclinical pharmacology of amphetamine: Implications for the treatment of neuropsychiatric disorders
Peter H. Hutson, Frank I. Tarazi, Manisha Madhoo, et al.
Pharmacology & Therapeutics (2014) Vol. 143, Iss. 3, pp. 253-264
Closed Access | Times Cited: 30
Page 1 - Next Page

Scroll to top